The Fort Worth Press - Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026

USD -
AED 3.672503
AFN 66.499323
ALL 80.629676
AMD 365.091035
AOA 917.000229
ARS 1491.486381
AUD 1.41547
AWG 1.80125
AZN 1.703341
BAM 1.691649
BBD 2.00813
BDT 123.418242
BHD 0.375989
BIF 2985.079791
BMD 1
BND 1.277602
BOB 11.849673
BRL 5.0833
BSD 0.997016
BTN 94.875232
BWP 13.457596
BYN 2.968819
BYR 19600
BZD 2.00519
CAD 1.39503
CDF 2262.504465
CHF 0.807385
CLF 0.023206
CLP 913.315746
CNY 6.747597
CNH 6.74284
COP 3142.844787
CRC 453.228387
CUC 1
CUP 26.5
CVE 95.372573
CZK 20.977978
DJF 177.546166
DKK 6.463765
DOP 58.20179
DZD 132.308956
EGP 49.540856
ERN 15
ETB 160.923669
EUR 0.864625
FJD 2.20855
FKP 0.74148
GBP 0.741015
GEL 2.610038
GGP 0.74148
GHS 11.700039
GIP 0.74148
GMD 73.504962
GNF 8756.649224
GTQ 7.607144
GYD 208.588851
HKD 7.845175
HNL 26.723176
HRK 6.5188
HTG 130.363707
HUF 314.570499
IDR 17801
ILS 2.99985
IMP 0.74148
INR 95.210497
IQD 1306.058902
IRR 1375550.000352
ISK 123.339726
JEP 0.74148
JMD 158.335856
JOD 0.709018
JPY 157.702498
KES 129.014401
KGS 87.449912
KHR 4049.647537
KMF 426.000355
KRW 1407.860403
KWD 0.30866
KYD 0.830861
KZT 467.275008
LAK 22510.919863
LBP 89282.792025
LKR 334.420274
LRD 179.959348
LSL 16.197552
LTL 2.95274
LVL 0.60489
LYD 6.341738
MAD 9.29222
MDL 17.337716
MGA 4254.638239
MKD 53.219738
MMK 2099.549369
MNT 3595.852714
MOP 8.056654
MRU 40.080439
MUR 47.069908
MVR 15.449749
MWK 1728.841413
MXN 17.1375
MYR 4.090099
MZN 63.904989
NAD 16.197552
NGN 1364.860163
NIO 36.690741
NOK 9.48825
NPR 151.800372
NZD 1.69713
OMR 0.382693
PAB 0.997016
PEN 3.376465
PGK 4.406003
PHP 60.704973
PKR 276.796523
PLN 3.717005
PYG 5928.296501
QAR 3.644596
RON 4.536297
RSD 101.492021
RUB 81.573714
RWF 1466.072741
SAR 3.744756
SBD 8.065696
SCR 14.449077
SDG 600.50044
SEK 9.459395
SGD 1.27801
SLE 24.590979
SOS 569.822255
SRD 37.866501
STD 20697.981008
STN 21.191022
SVC 8.723782
SZL 16.194265
THB 33.049662
TJS 9.197509
TMT 3.51
TND 2.929032
TRY 47.698745
TTD 6.757774
TWD 32.2506
TZS 2639.622886
UAH 44.653894
UGX 3714.050945
UYU 40.133201
UZS 11924.058297
VES 755.762396
VND 26204.5
VUV 118.557141
WST 2.733716
XAF 567.363231
XAG 0.015731
XAU 0.00023
XCD 2.70255
XCG 1.796912
XDR 0.705618
XOF 567.363231
XPF 103.152705
YER 238.392558
ZAR 16.14375
ZMK 9001.204229
ZMW 18.818492
ZWL 321.999592
  • CMSC

    0.0240

    21.744

    +0.11%

  • RYCEF

    0.2300

    20.85

    +1.1%

  • RIO

    1.4500

    101.1

    +1.43%

  • CMSD

    -0.1600

    21.82

    -0.73%

  • RBGPF

    0.7600

    70.5

    +1.08%

  • GSK

    0.7900

    52.96

    +1.49%

  • BCE

    -0.0200

    22.75

    -0.09%

  • VOD

    0.1900

    16.19

    +1.17%

  • NGG

    0.4700

    80.88

    +0.58%

  • BTI

    0.6000

    59.33

    +1.01%

  • JRI

    0.1500

    12.81

    +1.17%

  • RELX

    0.0485

    35.52

    +0.14%

  • BP

    -0.6000

    41.63

    -1.44%

  • BCC

    2.3400

    86.6

    +2.7%

  • AZN

    1.4100

    161.42

    +0.87%

Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026
Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026

Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026

Beverly Hills spine surgeon and principal investigator will present pooled clinical outcomes following recent FDA approval of motion-preserving cervical disc technology

Text size:

BEVERLY HILLS, CA / ACCESS Newswire / April 2, 2026 / Following the recent FDA Premarket Approval (PMA) of the Synergy Disc®, Todd H. Lanman, MD, a pioneer in motion-preserving spine surgery, will present the first full results from the U.S. Investigational Device Exemption (IDE) clinical trial at the International Society for the Advancement of Spine Surgery (ISASS) 2026 Annual Conference in Miami Beach, April 9-11. Dr. Lanman served as a principal investigator in the multicenter U.S. IDE study evaluating the motion-preserving cervical artificial disc, developed by Synergy Spine Solutions, for the treatment of single-level degenerative disc disease from C3-C7.

The Synergy Disc received FDA approval after demonstrating superiority to anterior cervical discectomy and fusion (ACDF) on the study's primary endpoint of composite clinical success at 24 months. In the IDE trial, the device achieved an 87.1% composite clinical success rate, significantly higher than the fusion control group.

Additional key findings included:

91.7% of patients achieved clinically meaningful improvement on the Neck Disability Index at two years compared with 75.2% in the fusion group

Lower mean neck pain scores in the Synergy Disc group (15.6 vs. 30.2 in the fusion cohort)

Lower worst arm pain scores (15.0 vs. 32.2)

Improved segmental alignment, with disc angle increasing from 2.6 degrees pre-operatively to 6.5 degrees at 24 months

Higher patient satisfaction, reported by 84.5% of Synergy Disc patients versus 61.6% of fusion patients

"Artificial disc replacement continues to evolve rapidly, and these IDE results tell a clear story - meaningful reductions in neck and arm pain, better function, and higher patient satisfaction over fusion," said Dr. Lanman. "For patients, that is just not a statistic. That is the ability to return to an active, unrestricted life. That is what motion preservation is ultimately about."

The Synergy device incorporates a lordotic polyethylene core engineered to preserve motion while improving spinal alignment, a design intended to reduce the risk of postoperative kyphosis and maintain physiologic cervical curvature.

Dr. Lanman's presentation at ISASS will provide spine surgeons with a detailed review of the IDE trial methodology, clinical outcomes, and implications for the future of cervical motion-preserving surgery.

The International Society for the Advancement of Spine Surgery (ISASS) Annual Conference is one of the premier scientific meetings dedicated to spine innovation and motion-preservation technologies. The 2026 meeting will bring together leading spine surgeons, researchers, and industry innovators to discuss emerging technologies and advances in spinal care.

About Dr. Todd H. Lanman

Todd Lanman, MD has over three decades of experience as a spinal neurosurgeon and has spent the last 25 years practicing spine surgery in Beverly Hills. In addition to being a world-renowned spinal surgeon, Dr. Lanman has also had 11 spinal surgeries including spinal fusions and artificial disc replacements. Because of these experiences as surgeon and as patient, Dr. Lanman brings a unique perspective to his surgical practice.

About Lanman Spinal Neurosurgery

Lanman Spinal Neurosurgery is committed to improving patients' quality of life by relieving pain and restoring spinal motion. The Beverly Hills practice has been at the leading edge of spine health for the past quarter of a century. Lanman Spinal Neurosurgery has and continues to pioneer artificial disc replacement and fusion revision surgeries to help neck and back pain sufferers live their best lives.

About Synergy Spine Solutions

Synergy Spine Solutions is a medical device company focused on improving the quality of life for patients undergoing spine surgery. The company develops motion-preserving technologies designed to treat degenerative disc disease while supporting the spine's natural curvature. Its flagship product, the FDA-approved Synergy Disc®, features a built-in 6-degree lordotic core designed to not only preserve motion but also improve sagittal alignment.

Media Contact:

Brandi Kamenar
Brandi Kamenar Brand Management
BrandiKamenar.com
Email: [email protected]
Phone: (310) 734-6180

SOURCE: Lanman Spinal Neurosurgery



View the original press release on ACCESS Newswire

P.Grant--TFWP